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analysis also identified an abnormal population of medium 
to large B cells expressing bright CD20, CD19, CD38, CD45 
without CD10, CD5, CD23 or overt kappa or lambda ex-
pression. His calcium levels improved with hydration and 
steroids. Chemotherapy was later initiated.
Conclusion
Primary adrenal lymphoma is rare and aggressive type of 
NHL. While adrenal insufficiency is expected in this clin-
ical scenario, hypercalcemia from 1,25-(OH)2-D excess is a 
relatively uncommon presentation. Adrenal insufficiency 
should be ruled out in bilateral infiltrative adrenal masses. 
Likely etiologies for hypercalcemia in our case appeared to 
be secondary to elevated 1,25-(OH)2-D production, humoral 
hypercalcemia of malignancy and worsened by untreated 
clinically evident adrenal insufficiency.
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Case study: Type Two Diabetes Patient in Remission After 
Twelve Years of Diagnosis
Introduction
Type 2 diabetes (T2D) has been defined as a lifelong condi-
tion which is inevitably progressive.1 The idea that beta cell 
function certainly declines with time in diabetic people who 
have developed T2D has been definitively disproven.2 It has 
been recognised that the processes that cause T2D can be 
reversed and T2D remission can be achieved.2
Many studies show that, by changing life style dramati-
cally, controlling diabetes can improve significantly and a 
significant proportion of patients can also reduce or come 
off their glucose-lowering therapies.3 This has been for-
mally proven in DIRECT, with clear evidence of gradual 
continuing improvement in beta cell functional capacity 
over at least 12 months.4 Remission was linked to weight 
loss, as two third of those who lost more than 10kg were in 
remission after two years.4
Methods
A case study was done on a 66 years old male, who is dia-
betic for the last 12 years, with other comorbidities: hyper-
tension and hypercholesterolemia.
He presented with Hemoglobin A1C (HbA1c) of 7.4% with 
BMI of 37.7 kg/m2 on four oral hypoglycaemic agents and 
basal insulin of 20 units per day.
His treatment was changed by adding Glucagon-like pep-
tide-1 receptor agonists (GLP-1 RA) for better glycemic 
control and weight reduction in a setting of a multidisci-
plinary team approach, including endocrinologist, diabetes 
educator, dietitian and physical trainer.
Results
Over the last one year and two months, patient was able to 
stop all his diabetes medication including GLP-1 RA. Over 
three years follow ups patient achieved weight reduction of 
17.3% with HbA1c of 6.5% and additional other metabolic 
factor benefits.
Conclusion
Even with 12 years of diabetes, reversibility of T2D can still 
be achieved with weight reduction of over 15%. We will wait 
for another 10 months to reconfirm our data for two years 
remission.
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The effects of DPP IV Inhibitor on glycemic variability in 
type 2 diabetic patients treated with twice daily premixed 
human insulin.
Abstract
Glycemic variability (GV) is emerging as an exciting ther-
apeutic target for diabetes mellitus (DM) with recent 
evidences showing association of GV with hypoglycemia 
risk as well as chronic complications.(1,2) Twice daily 
human premixed insulin is commonly used in developing 










-653/5833510 by guest on 07 August 2020
doi: 10.1210/jendso/bvaa046 | Journal of the Endocrine Society | A397
A397 JESOCI, Volume 4, Abstract Supplement, 2020
While more convenient and cost saving, human premixed 
insulin regime may increase GV due to lesser flexibility 
and less physiological pharmacokinetic profile. Dipeptidyl 
peptidase IV inhibitors (DPPIV-I) have been shown to 
improve GV when used for treatment of T2DM but the 
effects of DPPIV-I when added on human premixed insulin 
is limited. We therefore evaluated the changes in GV fol-
lowing addition of DPP IV-I among T2DM patients treated 
with premixed human insulin with or without metformin 
therapy. This was a prospective study involving adult 
patients with T2DM on stable doses of premixed human 
insulin with or without metformin for at least 3  months 
from two state hospitals in Malaysia. Blinded continuous 
glucose monitoring (CGM) were performed at baseline and 
following 6 weeks of adding Vildagliptin to their insulin 
regime. A total of 12 patients were recruited (50% male). 
Mean (SD) age was 55.8 (13) years with mean duration of 
disease of 14 (6.6) years. The addition of Vildagliptin signif-
icantly reduced GV indexes including SD 2.98 (1.17) to 2.33 
(0.82), p=0.017; MAGE 6.94 (2.61) to 5.72 (1.87), p=0.018; 
MAG 1.60 (0.76) to 1.23 (0.48), p=0.009 and M Value 13.96 
(13.01) to 6.52 (7.45), p=0.037. In addition there were 
improvements in terms of parameters for glycemic con-
trol. Time spent in optimal glycemic range (4-8  mmol/l) 
improved from 38.33 (19.69) to 58.17 (5.95) %, p=0.001 with 
reduction in AUC for hyperglycemia from 2.09 (1.73) to 1.06 
(1.09) mmol/day, p=0.010. Hypoglycemia events were in-
frequent and the reduction in time spent in hypoglycemia 
[5.92(9.74) to 1.91 (2.54)%, p=0.191] as well as AUC for 
hypoglycemia [0.03(0.54) to 0.01(0.02) mmol/day, p=0.163] 
were found although these did not reach statistical signifi-
cance. We concluded that addition of DPP IV-I to commonly 
prescribed twice daily premixed human insulin regime in 
patients with T2DM may improve GV and glycemic control 
and warrant further exploration.
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Background: In the IPEX (immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked) syndrome, Type 
1 diabetes mellitus is the most common endocrine compli-
cation and usually occurs with a variable presentation from 
immediately at birth to within the first few months of life.
Clinical case: A four-month-old male presented for evalua-
tion of failure to thrive, eczema, and diarrhea. In the ED, 
his glucose value was 246 mg/dL with beta-hydroxybutyrate 
of 0.29 mmol/L (0.00-0.30). Within eight hours and without 
insulin, he became hypoglycemic and required dextrose-
containing fluids to maintain euglycemia; he was quickly 
made NPO and started on TPN due to excessive stool 
output. For nearly two weeks he required no insulin while 
receiving 84g of dextrose per day (21 g/kg/day) in TPN. He 
developed bloody stools on the day that he started receiving 
Tacrolimus and IVIG and required transfer to the ICU, 
and an insulin need of 1 unit/kg/day developed with this 
worsening of his systemic illness. After the bloody stools re-
solved, immunosuppression with Rituximab was initiated. 
Once bowel function improved, Pedialyte and formula were 
slowly reintroduced and for three weeks his insulin re-
quirement varied from 0.2-0.4 units/kg/day. In his seventh 
week of hospitalization his insulin was discontinued due 
to hypoglycemia, and at the time of discharge he had been 
without insulin for ten days on ad lib formula feeding.
Hemoglobin A1c on admission was 10.2%, and repeat was 
10.3%. A  fructosamine level was obtained to evaluate 
the discrepancy between the initial HgbA1c and being 
euglycemic. It was 269 umol/L (190-270), equivalent to an 
approximate HgbA1c of 6.5%, suggesting that hypergly-
cemia resulting in an elevated HgbA1c occurred early in 
his life and had improved in the days to weeks prior to ad-
mission. Further testing revealed an elevated GAD-65 an-
tibody of >250 IU/mL (<5) but normal ICA 512 and insulin 
autoantibody.
His clinical picture was consistent with IPEX syndrome, 
confirmed with rapid whole genome sequencing showed a 
pathogenic hemizygous c.1010G>A p.Arg337Gln variant in 
the FOXP3 gene.
A HgbA1c performed prior to discharge, eight weeks after 
the initial, was 6.6%. This spontaneous resolution of hy-
perglycemia in IPEX, with insulin needs developing only 
when he had worsening systemic illness as demonstrated 
by bloody stools, has yet to be described.
Conclusion: Hyperglycemia fluctuated in the first few 
months of life in a patient with IPEX syndrome, likely 
related to severity of systemic illness and control of 
enteropathy.
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Background: Lipomatosis is a condition in which multiple 
lipomas are present on the body. Different entities which 
are accompanied by multiple lipomas include Proteus 
syndrome, Cowden syndrome and related disorders due 
to PTEN gene mutations, MEN1, benign symmetric 
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